The Moment Of Truth For Three Alzheimer’s Drugs Beckons: What To Expect

Eisai/Biogen And Roche Phase III Readouts Expected Soon

After the Aduhelm controversy, Eisai/Biogen, Roche and Lilly are lining up Phase III results for their candidates which, against the odds, they hope could finally represent real progress in Alzheimer’s treatment. Scrip takes a look at the key questions surrounding the field as the drugs await their fate.

Alzheimer's jigsaw
After the Aduhelm controversy, there is hope these drugs could offer a true breakthrough for people with early stage Alzheimer's. • Source: Shutterstock

While biopharma chatter around impending major Phase III results can get overheated, it is safe to say that readouts expected in late 2022 and early 2023 for three Alzheimer’s candidates will be a landmark moment for the industry and for millions of patients, whatever their outcome.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

Roche’s Brain Shuttle Delivers In Alzheimer’s, Moves Ahead To Phase III

 

By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.

Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure

 

The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By 

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By 

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.